MCID: BRS049
MIFTS: 56

Breast Carcinoma in Situ

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Breast Carcinoma in Situ

MalaCards integrated aliases for Breast Carcinoma in Situ:

Name: Breast Carcinoma in Situ 12 44 15
Non-Infiltrating Carcinoma of Breast 12
Carcinoma in Situ of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8791
ICD10 33 D05 D05.9
ICD9CM 35 233.0
MeSH 44 D000071960
UMLS 73 C0154084

Summaries for Breast Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the breast.

MalaCards based summary : Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to comedo carcinoma and lobular neoplasia. An important gene associated with Breast Carcinoma in Situ is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Anastrozole and Tamoxifen have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Breast Carcinoma in Situ

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 203)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 32.3 ERBB2 ESR1
2 lobular neoplasia 31.9 BRCA1 ERBB2 ESR1
3 ductal carcinoma in situ 30.6 BRCA1 BRCA2 EGFR ERBB2 ESR1 KRT5
4 in situ carcinoma 30.0 BRCA1 EGFR ERBB2 ESR1 KRT5 PGR
5 breast ductal carcinoma 29.4 BRCA1 EGFR ERBB2 ESR1 MET PGR
6 female breast cancer 29.3 BRCA1 BRCA2 ERBB2 ESR1 PGR TP53
7 ovarian cancer 28.7 BRCA1 BRCA2 EGFR ERBB2 ESR1 KDR
8 breast cancer 27.4 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
9 breast apocrine carcinoma in situ 11.9
10 breast-ovarian cancer, familial 1 10.4 BRCA1 BRCA2
11 pleomorphic adenoma carcinoma 10.3 ERBB2 TP53
12 gastric papillary adenocarcinoma 10.3 ERBB2 TP53
13 hereditary site-specific ovarian cancer syndrome 10.3 BRCA1 BRCA2
14 hemifacial spasm 10.3 FLT4 VEGFA
15 critical limb ischemia 10.3 IL6 VEGFA
16 infiltrating angiolipoma 10.3 VEGFA VEGFC
17 angiokeratoma circumscriptum 10.3 KDR VEGFA
18 gorham's disease 10.3 FLT4 VEGFC
19 congenital lymphedema 10.3 FLT4 VEGFC
20 tuberculous salpingitis 10.3 BRCA1 BRCA2 ERBB2
21 fallopian tube adenocarcinoma 10.2 BRCA1 BRCA2 ERBB2
22 renal cell carcinoma, papillary, 1 10.2 ERBB2 MET TP53
23 uterine corpus serous adenocarcinoma 10.2 BRCA1 ERBB2 TP53
24 mutagen sensitivity 10.2 BRCA1 BRCA2 TP53
25 male reproductive system disease 10.2 IL6 TP53 VEGFA
26 osteoporotic fracture 10.2 ESR1 IL6
27 intracystic papillary adenoma 10.2 ERBB2 PGR
28 breast malignant phyllodes tumor 10.2 PGR TP53
29 hemangioma 10.2 FLT4 KDR VEGFA
30 breast intraductal proliferative lesion 10.2 EGFR ERBB2
31 transitional cell carcinoma 10.1 EGFR ERBB2 TP53
32 breast reconstruction 10.1 BRCA1 BRCA2
33 gliosarcoma 10.1 EGFR FGFR1 TP53
34 scirrhous adenocarcinoma 10.1 ERBB2 PGR
35 lymphangiosarcoma 10.1 FLT4 VEGFA VEGFC
36 breast apocrine carcinoma 10.1 ERBB2 PGR
37 endometrium carcinoma in situ 10.1 PGR TP53
38 breast cystic hypersecretory carcinoma 10.1 ERBB2 KRT5
39 brain ependymoma 10.1 EGFR TP53
40 angiosarcoma 10.1 FLT4 KDR VEGFA
41 keratinizing squamous cell carcinoma 10.1 KRT5 TP53
42 malignant spiradenoma 10.1 KRT5 TP53
43 orbital lymphangioma 10.1 EGFR FLT4
44 nosophobia 10.1 BRCA1 BRCA2 PGR
45 cancerophobia 10.1 BRCA1 BRCA2 PGR
46 vascular cancer 10.1 FLT4 KDR VEGFA
47 hematologic cancer 10.1 FGFR1 KDR TP53 VEGFA
48 soft tissue sarcoma 10.1 EGFR TP53 VEGFA
49 hereditary breast ovarian cancer syndrome 10.1 BRCA1 BRCA2 TP53
50 mucinous lung adenocarcinoma 10.1 EGFR ERBB2 FGFR1

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to Breast Carcinoma in Situ

Symptoms & Phenotypes for Breast Carcinoma in Situ

GenomeRNAi Phenotypes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.64 ESR1 FGFR1 KDR
2 Decreased viability GR00221-A-2 9.64 BRCA1 ESR1 FGFR1 FLT4 KDR
3 Decreased viability GR00221-A-3 9.64 BRCA1 KDR
4 Decreased viability GR00221-A-4 9.64 ESR1 KDR
5 Decreased viability GR00301-A 9.64 BRCA1
6 Decreased viability GR00342-S-1 9.64 FLT4
7 Decreased viability GR00342-S-2 9.64 FLT4
8 Decreased viability GR00342-S-3 9.64 FLT4
9 Decreased viability GR00402-S-2 9.64 BRCA1 ESR1 FGFR1 FLT4 KDR
10 Decreased substrate adherent cell growth GR00193-A-1 9.35 MET
11 Decreased substrate adherent cell growth GR00193-A-3 9.35 MET
12 Decreased substrate adherent cell growth GR00193-A-4 9.35 FGFR1 KDR MET

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.52 BRCA1 EGFR ERBB2 ESR1 FGFR1 FLT4
2 cellular MP:0005384 10.49 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
3 growth/size/body region MP:0005378 10.48 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
4 behavior/neurological MP:0005386 10.47 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6
5 digestive/alimentary MP:0005381 10.47 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
6 embryo MP:0005380 10.47 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
7 homeostasis/metabolism MP:0005376 10.46 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
8 mortality/aging MP:0010768 10.45 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
9 integument MP:0010771 10.44 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
10 endocrine/exocrine gland MP:0005379 10.43 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
11 immune system MP:0005387 10.42 BRCA1 BRCA2 EGFR ESR1 FGFR1 FLT4
12 hematopoietic system MP:0005397 10.35 BRCA1 BRCA2 EGFR ESR1 FGFR1 IL6
13 limbs/digits/tail MP:0005371 10.3 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
14 muscle MP:0005369 10.29 BRCA1 EGFR ERBB2 ESR1 FGFR1 FLT4
15 nervous system MP:0003631 10.28 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
16 adipose tissue MP:0005375 10.23 BRCA1 EGFR ESR1 FLT4 IL6 IL6ST
17 neoplasm MP:0002006 10.23 BRCA1 BRCA2 EGFR ERBB2 ESR1 IL6
18 craniofacial MP:0005382 10.21 EGFR ERBB2 FGFR1 KDR KRT5 MET
19 liver/biliary system MP:0005370 10.21 EGFR ESR1 FLT4 IL6 IL6ST KDR
20 normal MP:0002873 10.21 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
21 no phenotypic analysis MP:0003012 10.14 EGFR ESR1 FGFR1 FLT4 KDR KRT19
22 reproductive system MP:0005389 10.1 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
23 renal/urinary system MP:0005367 9.92 BRCA1 EGFR ESR1 FGFR1 IL6 MET
24 respiratory system MP:0005388 9.85 BRCA1 EGFR ERBB2 ESR1 IL6 KDR
25 skeleton MP:0005390 9.8 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
26 vision/eye MP:0005391 9.28 EGFR FGFR1 IL6 IL6ST KDR LIF

Drugs & Therapeutics for Breast Carcinoma in Situ

Drugs for Breast Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 204)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
2
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
3
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112809-51-5 3902
4
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2 107868-30-4 60198
5
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
6 Citrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anticoagulants Phase 4,Phase 3,Phase 2,Not Applicable
20 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Chelating Agents Phase 4,Phase 3,Phase 2,Not Applicable
22
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-28-2 5757
23
Polyestradiol phosphate Approved Phase 3,Phase 2,Not Applicable 28014-46-2
24 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 979-32-8
25
Trastuzumab Approved, Investigational Phase 3,Phase 2,Not Applicable 180288-69-1 9903
26
Progesterone Approved, Vet_approved Phase 3,Phase 2,Not Applicable,Early Phase 1 57-83-0 5994
27
Norethindrone Approved Phase 3 68-22-4 6230
28
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
29
mometasone furoate Approved, Vet_approved Phase 3 83919-23-7
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
31
Metformin Approved Phase 3,Phase 1 657-24-9 14219 4091
32
Pembrolizumab Approved Phase 3,Early Phase 1 1374853-91-4
33
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
34 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
35 Estradiol 3-benzoate Phase 3,Phase 2,Not Applicable
36 Estradiol 17 beta-cypionate Phase 3,Phase 2,Not Applicable
37 Immunologic Factors Phase 3,Phase 2,Phase 1
38 Norethindrone acetate Phase 3
39 Contraceptive Agents Phase 3,Early Phase 1
40 Contraceptives, Oral Phase 3,Early Phase 1
41 Contraceptive Agents, Male Phase 3
42
Medroxyprogesterone Phase 3 520-85-4 10631
43 Dermatologic Agents Phase 3,Phase 2
44 Anti-Allergic Agents Phase 3
45 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Estrogens, Conjugated (USP) Phase 3,Phase 2
47 Cola Phase 3
48 Central Nervous System Depressants Phase 3,Not Applicable
49 Adjuvants, Anesthesia Phase 3
50 Liver Extracts Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 244)
# Name Status NCT ID Phase Drugs
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
3 Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
4 Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
5 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
6 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed NCT00003771 Phase 3 norethindrone acetate
7 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
8 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
9 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
10 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate
11 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
14 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
15 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
16 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3
17 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
18 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS) Active, not recruiting NCT00907868 Phase 3
19 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
20 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
21 Oxybutynin Chloride in Managing Hot Flashes Active, not recruiting NCT02961790 Phase 3 Oxybutynin Chloride
22 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
23 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
24 Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation Active, not recruiting NCT00673335 Phase 3 letrozole;Placebo
25 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
26 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3 risedronate sodium
27 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
28 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
29 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
30 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
31 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
32 Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer Completed NCT02556632 Phase 2 Curcumin-based Gel
33 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ Completed NCT01439711 Phase 2 letrozole
34 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Completed NCT02150525 Phase 2
35 Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
36 Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer Completed NCT01869764 Phase 2
37 Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer Completed NCT00084539 Phase 2
38 Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy Completed NCT00843167 Phase 2
39 Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer Completed NCT00054301 Phase 2
40 Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease Completed NCT00031720 Phase 2 Tamoxifen
41 Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer Completed NCT00334542 Phase 2 simvastatin
42 Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer Completed NCT00354640 Phase 2 anastrozole;simvastatin
43 Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Completed NCT00764322 Phase 2 tamoxifen citrate
44 Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer Completed NCT00244959 Phase 2 anastrozole
45 Letrozole in Preventing Breast Cancer in Postmenopausal Women Completed NCT00090857 Phase 2 Letrozole
46 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast Completed NCT03002766 Phase 2
47 Treatment With Pazopanib for Neoadjuvant Breast Cancer Completed NCT00849472 Phase 2 doxorubicin + cyclophosphamide;paclitaxel + pazopanib;pazopanib monotherapy
48 Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) Completed NCT01023477 Phase 1, Phase 2 Chloroquine Standard Dose (500mg/week);Chloroquine Low Dose (250mg/week)
49 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2 letrozole;zoledronic acid
50 MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ Completed NCT00586326 Phase 2

Search NIH Clinical Center for Breast Carcinoma in Situ

Cochrane evidence based reviews: breast carcinoma in situ

Genetic Tests for Breast Carcinoma in Situ

Anatomical Context for Breast Carcinoma in Situ

MalaCards organs/tissues related to Breast Carcinoma in Situ:

41
Breast, Bone, Lung, Skin, Brain, Ovary, Thyroid

The Foundational Model of Anatomy Ontology organs/tissues related to Breast Carcinoma in Situ:

19
The Breast

Publications for Breast Carcinoma in Situ

Articles related to Breast Carcinoma in Situ:

(show all 47)
# Title Authors Year
1
Overtreatment in surgery - does it concern also the patients with ductal breast carcinoma in situ. ( 29513252 )
2018
2
Claudin-4 Expression Is Associated With Disease-Free Survival in Breast Carcinoma-in-Situ: Mean Follow-up of 8.2 Years. ( 30025999 )
2018
3
Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. ( 28286675 )
2017
4
Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes. ( 27926499 )
2016
5
Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation. ( 27639877 )
2016
6
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. ( 26062614 )
2015
7
Mondor's disease in a patient previously treated for breast carcinoma in situ: a case report. ( 22595929 )
2012
8
Differences in breast carcinoma in situ between menopausal and premenopausal women. ( 21617240 )
2011
9
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. ( 21149333 )
2010
10
Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ? ( 19896281 )
2010
11
Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. ( 20565829 )
2010
12
Prevalence of breast carcinoma in situ in the United States. ( 19706857 )
2009
13
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). ( 18317962 )
2008
14
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. ( 18665169 )
2008
15
Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. ( 17063272 )
2007
16
Cigarette smoking and risk of breast carcinoma in situ. ( 17700252 )
2007
17
Oral contraceptive use and risk of breast carcinoma in situ. ( 18006914 )
2007
18
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. ( 17244359 )
2007
19
Quality of life for women diagnosed with breast carcinoma in situ. ( 17050872 )
2006
20
Oral contraceptive use and risk of breast carcinoma in situ (United States). ( 17006721 )
2006
21
Molecular classification of breast carcinoma in situ. ( 17375183 )
2006
22
Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. ( 15540225 )
2005
23
Impact of reproductive factors and lactation on breast carcinoma in situ risk. ( 15054874 )
2004
24
Lifetime recreational exercise activity and risk of breast carcinoma in situ. ( 14601085 )
2003
25
Oral contraceptives and the risk of ductal breast carcinoma in situ. ( 14572155 )
2003
26
Proliferative lesions of the breast: carcinoma in situ. ( 15022899 )
2003
27
The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. ( 14659121 )
2003
28
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. ( 12611452 )
2003
29
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. ( 12670886 )
2003
30
DNA content and cell number determination in microdissected samples of breast carcinoma in situ. ( 12118344 )
2002
31
Breast carcinoma in situ: risk factors and screening patterns. ( 11734598 )
2001
32
Computerized image analysis of Ki-67 in ductal breast carcinoma in situ. ( 11444192 )
2001
33
Risk of subsequent invasive breast cancer after breast carcinoma in situ. ( 10703809 )
2000
34
p53 mutations and expression in breast carcinoma in situ. ( 10623666 )
2000
35
Breast carcinoma in situ in a male. Report of a case diagnosed by nipple discharge cytology. ( 9622698 )
1998
36
Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. ( 9071907 )
1997
37
Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. ( 8692711 )
1996
38
Biological heterogeneity of breast carcinoma in situ. ( 8651598 )
1996
39
Male breast carcinoma in situ. Report of a case diagnosed by nipple discharge cytology alone. ( 7654052 )
1995
40
Breast carcinoma-in-situ: an emerging problem in Singapore. ( 1329232 )
1992
41
Breast carcinoma in situ. ( 20169700 )
1992
42
Receptors for estrogen and progesterone in breast carcinoma in situ. ( 1295456 )
1992
43
Ten-year follow-up of breast carcinoma in situ in Connecticut. ( 1365682 )
1992
44
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. ( 1657650 )
1991
45
Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. ( 1677296 )
1991
46
Breast carcinoma in situ. ( 2535929 )
1989
47
Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. ( 2990246 )
1985

Variations for Breast Carcinoma in Situ

Expression for Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for Breast Carcinoma in Situ

Pathways related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.23 EGFR ERBB2 ESR1 FGFR1 FLT4 IL6
2
Show member pathways
13.92 EGFR ERBB2 FGFR1 FLT4 IL6 IL6ST
3
Show member pathways
13.9 BRCA1 EGFR ERBB2 ESR1 FGFR1 FLT4
4
Show member pathways
13.73 EGFR ERBB2 FGFR1 FLT4 IL6 IL6ST
5
Show member pathways
13.73 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
6
Show member pathways
13.61 BRCA1 EGFR ERBB2 FGFR1 FLT4 IL6
7
Show member pathways
13.6 EGFR ERBB2 FGFR1 FLT4 IL6 KDR
8
Show member pathways
13.55 EGFR ERBB2 FGFR1 KDR KRT19 KRT5
9
Show member pathways
13.48 EGFR ERBB2 FGFR1 FLT4 IL6 KDR
10
Show member pathways
13.43 EGFR ERBB2 FGFR1 IL6 IL6ST LIF
11
Show member pathways
13.39 EGFR ERBB2 FGFR1 FLT4 IL6 KDR
12
Show member pathways
13.38 EGFR ERBB2 FGFR1 FLT4 IL6 KDR
13
Show member pathways
13.35 EGFR ERBB2 ESR1 FGFR1 FLT4 IL6
14
Show member pathways
13.15 EGFR FGFR1 FLT4 IL6 KDR MET
15
Show member pathways
13.11 EGFR FGFR1 FLT4 IL6 KDR MET
16
Show member pathways
13.09 EGFR ESR1 KRT19 PGR VEGFA VEGFC
17
Show member pathways
13.05 EGFR ERBB2 FGFR1 FLT4 KDR MET
18
Show member pathways
12.98 EGFR ERBB2 FLT4 KDR MET VEGFA
19
Show member pathways
12.94 EGFR ERBB2 FGFR1 IL6 IL6ST LIF
20
Show member pathways
12.94 BRCA2 EGFR ERBB2 FGFR1 TP53 VEGFA
21
Show member pathways
12.93 EGFR ERBB2 IL6ST MET VEGFA
22
Show member pathways
12.84 BRCA1 EGFR ERBB2 FGFR1 FLT4 IL6
23
Show member pathways
12.83 EGFR FGFR1 FLT4 KDR MET VEGFA
24
Show member pathways
12.8 EGFR FGFR1 FLT4 IL6 KDR MET
25 12.8 EGFR ERBB2 FGFR1 FLT4 KDR MET
26
Show member pathways
12.78 EGFR ERBB2 FGFR1 MET TP53
27 12.62 BRCA1 EGFR ERBB2 MET TP53 VEGFA
28
Show member pathways
12.6 EGFR ERBB2 FGFR1 FLT4 KDR MET
29
Show member pathways
12.55 EGFR ERBB2 MET TP53 VEGFA
30
Show member pathways
12.53 EGFR ERBB2 FGFR1 FLT4 KDR MET
31
Show member pathways
12.52 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
32
Show member pathways
12.49 EGFR FLT4 KDR VEGFA VEGFC
33
Show member pathways
12.49 EGFR ERBB2 FGFR1 FLT4 IL6 KDR
34
Show member pathways
12.48 EGFR FGFR1 FLT4 KDR MET VEGFA
35
Show member pathways
12.44 BRCA1 ESR1 KDR VEGFA
36
Show member pathways
12.43 EGFR IL6 IL6ST LIF
37
Show member pathways
12.37 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
38
Show member pathways
12.33 EGFR FGFR1 KDR VEGFA VEGFC
39
Show member pathways
12.31 EGFR FGFR1 FLT4 IL6 KDR MET
40 12.28 BRCA1 BRCA2 EGFR ESR1 TP53 VEGFA
41 12.27 EGFR ERBB2 ESR1 FGFR1 KDR MET
42 12.25 EGFR IL6 TP53 VEGFA
43
Show member pathways
12.19 EGFR ERBB2 IL6 IL6ST
44
Show member pathways
12.19 EGFR ERBB2 FGFR1 FLT4 IL6ST KDR
45 12.18 IL6 KDR KRT19 LIF MET VEGFA
46 12.15 EGFR LIF MET TP53
47 12.15 EGFR ERBB2 FGFR1 FLT4 KDR MET
48
Show member pathways
12.14 BRCA1 EGFR FGFR1 FLT4 IL6 KDR
49 12.12 BRCA2 EGFR ERBB2 ESR1 FGFR1 FLT4
50 12.08 EGFR ERBB2 FGFR1 FLT4 IL6ST KDR

GO Terms for Breast Carcinoma in Situ

Cellular components related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 EGFR FGFR1 FLT4 IL6 IL6ST KDR
2 lateral element GO:0000800 9.37 BRCA1 BRCA2
3 basal plasma membrane GO:0009925 9.33 EGFR ERBB2 MET
4 interleukin-6 receptor complex GO:0005896 9.26 IL6 IL6ST
5 receptor complex GO:0043235 9.17 EGFR ERBB2 FGFR1 FLT4 IL6ST KDR
6 cytoplasm GO:0005737 10.13 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1

Biological processes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of angiogenesis GO:0045766 9.97 BRCA1 KDR VEGFA VEGFC
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 EGFR ERBB2 FGFR1 FLT4 KDR MET
3 protein autophosphorylation GO:0046777 9.96 EGFR ERBB2 FGFR1 FLT4 KDR
4 positive regulation of protein kinase B signaling GO:0051897 9.95 EGFR ERBB2 ESR1 FGFR1 MET
5 lung development GO:0030324 9.93 EGFR FGFR1 LIF VEGFA
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.92 IL6 LIF TP53 VEGFA
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.92 EGFR IL6 LIF VEGFA
8 positive regulation of endothelial cell proliferation GO:0001938 9.91 FLT4 KDR VEGFA VEGFC
9 phosphatidylinositol phosphorylation GO:0046854 9.91 EGFR ERBB2 ESR1 FGFR1 MET
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 IL6 IL6ST LIF VEGFA
11 positive regulation of epithelial cell proliferation GO:0050679 9.89 EGFR ERBB2 VEGFA VEGFC
12 positive regulation of MAP kinase activity GO:0043406 9.88 EGFR ERBB2 FGFR1 VEGFA
13 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.88 FLT4 KDR VEGFA VEGFC
14 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.88 EGFR ERBB2 FLT4 KDR MET
15 positive regulation of protein phosphorylation GO:0001934 9.88 EGFR ERBB2 FLT4 KDR VEGFA VEGFC
16 response to estrogen GO:0043627 9.87 BRCA1 ESR1 KRT19
17 positive regulation of endothelial cell migration GO:0010595 9.86 FLT4 KDR VEGFA
18 positive chemotaxis GO:0050918 9.85 MET VEGFA VEGFC
19 peptidyl-tyrosine phosphorylation GO:0018108 9.85 EGFR ERBB2 FGFR1 FLT4 KDR MET
20 positive regulation of blood vessel endothelial cell migration GO:0043536 9.84 FGFR1 KDR VEGFA VEGFC
21 lung alveolus development GO:0048286 9.83 FLT4 LIF PGR
22 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.83 FLT4 KDR VEGFA
23 sprouting angiogenesis GO:0002040 9.82 FLT4 VEGFA VEGFC
24 positive regulation of vascular endothelial growth factor production GO:0010575 9.82 BRCA1 FLT4 IL6ST
25 positive regulation of cell proliferation GO:0008284 9.81 EGFR FGFR1 FLT4 IL6 IL6ST KDR
26 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.74 BRCA1 BRCA2 TP53
27 negative regulation of signal transduction GO:0009968 9.73 EGFR ERBB2 FGFR1 FLT4 KDR MET
28 interleukin-6-mediated signaling pathway GO:0070102 9.72 IL6 IL6ST
29 induction of positive chemotaxis GO:0050930 9.72 VEGFA VEGFC
30 positive regulation of phospholipase C activity GO:0010863 9.72 ESR1 FGFR1
31 positive regulation of acute inflammatory response GO:0002675 9.71 IL6 IL6ST
32 positive regulation of astrocyte differentiation GO:0048711 9.71 IL6ST LIF
33 positive regulation of positive chemotaxis GO:0050927 9.71 KDR VEGFA
34 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.71 ESR1 TP53
35 salivary gland morphogenesis GO:0007435 9.71 EGFR FGFR1
36 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.7 EGFR TP53
37 positive regulation of protein kinase C signaling GO:0090037 9.7 FLT4 VEGFA
38 negative regulation of ERBB signaling pathway GO:1901185 9.69 EGFR ERBB2
39 positive regulation of mast cell chemotaxis GO:0060754 9.69 VEGFA VEGFC
40 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.68 KDR VEGFA
41 leukemia inhibitory factor signaling pathway GO:0048861 9.67 IL6ST LIF
42 negative regulation of apoptotic process GO:0043066 9.65 EGFR ERBB2 FGFR1 FLT4 IL6 IL6ST
43 vascular endothelial growth factor signaling pathway GO:0038084 9.62 FLT4 KDR VEGFA VEGFC
44 chordate embryonic development GO:0043009 9.61 BRCA1 BRCA2 FGFR1
45 positive regulation of MAPK cascade GO:0043410 9.23 EGFR ERBB2 FGFR1 FLT4 IL6 KDR
46 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 BRCA1 EGFR ESR1 IL6 LIF MET
47 phosphorylation GO:0016310 10.16 EGFR ERBB2 FGFR1 FLT4 KDR MET
48 protein phosphorylation GO:0006468 10.15 EGFR ERBB2 FGFR1 FLT4 KDR MET
49 positive regulation of transcription, DNA-templated GO:0045893 10.14 BRCA1 BRCA2 EGFR ESR1 IL6 TP53
50 cell differentiation GO:0030154 10.11 EGFR ERBB2 FGFR1 FLT4 KDR MET

Molecular functions related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.95 EGFR ERBB2 FGFR1 FLT4 KDR MET
2 enzyme binding GO:0019899 9.89 BRCA1 EGFR ESR1 PGR TP53
3 transmembrane signaling receptor activity GO:0004888 9.85 EGFR ERBB2 FGFR1 FLT4 KDR MET
4 growth factor activity GO:0008083 9.81 IL6 LIF VEGFA VEGFC
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.76 EGFR ERBB2 FGFR1 MET
6 growth factor binding GO:0019838 9.73 ERBB2 FLT4 IL6ST KDR
7 protein tyrosine kinase activity GO:0004713 9.73 EGFR ERBB2 FGFR1 FLT4 KDR MET
8 protein phosphatase binding GO:0019903 9.72 EGFR ERBB2 FLT4 MET TP53
9 identical protein binding GO:0042802 9.7 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
10 nitric-oxide synthase regulator activity GO:0030235 9.57 EGFR ESR1
11 interleukin-6 receptor binding GO:0005138 9.56 IL6 IL6ST
12 vascular endothelial growth factor-activated receptor activity GO:0005021 9.55 FLT4 KDR
13 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.55 EGFR ERBB2 ESR1 FGFR1 MET
14 vascular endothelial growth factor receptor 3 binding GO:0043185 9.54 VEGFA VEGFC
15 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.1 EGFR ERBB2 FGFR1 FLT4 KDR MET
16 protein binding GO:0005515 10.36 BRCA1 BRCA2 EGFR ERBB2 ESR1 FGFR1
17 ATP binding GO:0005524 10.12 EGFR ERBB2 FGFR1 FLT4 KDR MET
18 kinase activity GO:0016301 10 EGFR ERBB2 FGFR1 FLT4 KDR MET

Sources for Breast Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....